Format

Send to

Choose Destination
Hepatology. 2014 Nov;60(5):1776-82. doi: 10.1002/hep.27246. Epub 2014 Sep 26.

Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.

Author information

1
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.

Abstract

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical studies have shown the potential benefit of modulating the immunogenicity of HCC. In addition, recent advances in tumor immunology have broadened our understanding of the complex mechanism of immune evasion. In this review we summarize the current knowledge on HCC immunology and discuss the potential of immune checkpoint blockade as a novel HCC therapy from the basic, translational, and clinical perspectives.

PMID:
24912948
PMCID:
PMC4211962
DOI:
10.1002/hep.27246
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center